These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 20234356)

  • 21. The pathophysiology of aldosterone in the cardiovascular system.
    Rocha R; Funder JW
    Ann N Y Acad Sci; 2002 Sep; 970():89-100. PubMed ID: 12381544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. This is not Dr. Conn's aldosterone anymore.
    Brown NJ
    Trans Am Clin Climatol Assoc; 2011; 122():229-43. PubMed ID: 21686229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
    Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G
    Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
    Bravo EL
    Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
    Barrera-Chimal J; Girerd S; Jaisser F
    Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
    Keidar S; Kaplan M; Pavlotzky E; Coleman R; Hayek T; Hamoud S; Aviram M
    Circulation; 2004 May; 109(18):2213-20. PubMed ID: 15123520
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice.
    Kagiyama S; Matsumura K; Goto K; Otsubo T; Iida M
    Regul Pept; 2010 Feb; 160(1-3):133-9. PubMed ID: 19969025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
    Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
    Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
    Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
    Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
    Jaffe IZ; Mendelsohn ME
    Circ Res; 2005 Apr; 96(6):643-50. PubMed ID: 15718497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects.
    Davel AP; Jaffe IZ; Tostes RC; Jaisser F; Belin de Chantemèle EJ
    Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H989-H999. PubMed ID: 29957022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mineralocorticoid receptor antagonist for renal protection.
    Ma TK; Szeto CC
    Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Renin angiotensin antagonists normalize aberrant activation of epithelial sodium channels in sodium-sensitive hypertension.
    Ushio-Yamana H; Minegishi S; Ishigami T; Araki N; Umemura M; Tamura K; Maeda E; Kakizoe Y; Kitamura K; Umemura S
    Nephron Exp Nephrol; 2012; 122(3-4):95-102. PubMed ID: 23594971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular and cardiac benefits of angiotensin receptor blockers.
    Schiffrin EL
    Am J Med; 2002 Oct; 113(5):409-18. PubMed ID: 12401536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mineralocorticoid Receptor and Cardiovascular Disease.
    Buonafine M; Bonnard B; Jaisser F
    Am J Hypertens; 2018 Oct; 31(11):1165-1174. PubMed ID: 30192914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid Receptor Blockade in End-Stage Renal Disease.
    Lyubarova R; Gosmanova EO
    Curr Hypertens Rep; 2017 May; 19(5):40. PubMed ID: 28451852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid non-genomic vasoconstrictor actions of aldosterone in the renal microcirculation.
    Arima S
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):170-4. PubMed ID: 17045798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Sides of Aldosterone Action in Cardiovascular System as Potential Targets for Therapeutic Intervention.
    Kolodziejczyk P; Gromotowicz-Poplawska A; Aleksiejczuk M; Chabielska E; Tutka P; Miltyk W
    Curr Drug Targets; 2018; 19(16):1968-1979. PubMed ID: 29577853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
    Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
    Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.